Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             58 results found
no title author magazine year volume issue page(s) type
1 Active surveillance for squamous-cell head and neck carcinoma Burki, Talha Khan
 2016
 17 5 p. e183-
1 p.
 article
2 Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial Park, Keunchil
 2016
 17 5 p. 577-589
13 p.
 article
3 2016 Annual Meeting of the Society of Gynecologic Oncology Sklan, Alex
 2016
 17 5 p. 562-
1 p.
 article
4 Before I kick the bucket: the whole story Kirby, Tony
 2016
 17 5 p. 566-
1 p.
 article
5 Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study Bertucci, François
 2016
 17 5 p. 600-611
12 p.
 article
6 Beyond a moonshot: insurance coverage for proton therapy Shah, Anand
 2016
 17 5 p. 559-561
3 p.
 article
7 Brexit: a European perspective Tabernero, Josep
 2016
 17 5 p. 558-559
2 p.
 article
8 CAN.recall Hiew, Samantha
 2016
 17 5 p. 564-
1 p.
 article
9 Chemoradiotherapy for grade 2 glioma improves survival Baker, Holly
 2016
 17 5 p. e186-
1 p.
 article
10 Chemotherapy benefit for paediatric neurofibromatosis type I Brower, Vicki
 2016
 17 5 p. e186-
1 p.
 article
11 Chemotherapy risks to fertility of childhood cancer survivors Anderson, Richard A
 2016
 17 5 p. 540-541
2 p.
 article
12 Correction to Lancet Oncol 2016; 17: 541 2016
 17 5 p. e181-
1 p.
 article
13 Correction to Lancet Oncol 2016; 17: 456 2016
 17 5 p. e181-
1 p.
 article
14 Correction to Lancet Oncol 2016; 17: 416 2016
 17 5 p. e181-
1 p.
 article
15 Crizotinib improves intracranial metastasis control Brower, Vicki
 2016
 17 5 p. e184-
1 p.
 article
16 Dabrafenib in patients with BRAF V600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial Planchard, David
 2016
 17 5 p. 642-650
9 p.
 article
17 Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis Callegaro, Dario
 2016
 17 5 p. 671-680
10 p.
 article
18 Dual inhibition of oncogenic targets for B-cell malignancies Richardson, Paul G
 2016
 17 5 p. 547-549
3 p.
 article
19 Ethical issues of clinical trials in paediatric oncology from 2003 to 2013: a systematic review Dupont, Jean-Claude K
 2016
 17 5 p. e187-e197
nvt p.
 article
20 Impact of Brexit on cancer care and research The Lancet Oncology,
 2016
 17 5 p. 539-
1 p.
 article
21 Improved drug access in low and middle-income countries The Lancet Oncology,
 2016
 17 5 p. 539-
1 p.
 article
22 Inflammatory breast cancer: a new approach Cristofanilli, Massimo
 2016
 17 5 p. 544-546
3 p.
 article
23 Justifying vein resection with pancreatoduodenectomy Crippa, Stefano
 2016
 17 5 p. e177-e178
nvt p.
 article
24 Justifying vein resection with pancreatoduodenectomy – Author's reply Barreto, Savio G
 2016
 17 5 p. e178-
1 p.
 article
25 Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254 Thanarajasingam, Gita
 2016
 17 5 p. 663-670
8 p.
 article
26 Low public awareness of link between cancer and alcohol Burki, Talha Khan
 2016
 17 5 p. e184-
1 p.
 article
27 Lung cancer CT screening: is annual screening necessary? Field, John K
 2016
 17 5 p. 543-544
2 p.
 article
28 Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial Patz Jr, Edward F
 2016
 17 5 p. 590-599
10 p.
 article
29 Ma Ma Howe, Rhiannon
 2016
 17 5 p. 565-
1 p.
 article
30 Neratinib after trastuzumab in patients with HER2-positive breast cancer Hasegawa, Takahiro
 2016
 17 5 p. e176-
1 p.
 article
31 Neratinib after trastuzumab in patients with HER2-positive breast cancer – Author's reply Chan, Arlene
 2016
 17 5 p. e176-e177
nvt p.
 article
32 Nominal nomograms and marginal margins: what is the law of the line? Randall, R Lor
 2016
 17 5 p. 554-556
3 p.
 article
33 Pazopanib for both GIST and soft-tissue sarcoma Nishida, Toshirou
 2016
 17 5 p. 549-550
2 p.
 article
34 Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial Mir, Olivier
 2016
 17 5 p. 632-641
10 p.
 article
35 Ponatinib for chronic myeloid leukaemia: future perspectives Fava, Carmen
 2016
 17 5 p. 546-547
2 p.
 article
36 Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial Lipton, Jeffrey H
 2016
 17 5 p. 612-621
10 p.
 article
37 Potential treatment for a subtype of glioblastoma tumours Granovetter, Michael
 2016
 17 5 p. e182-
1 p.
 article
38 Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort Chow, Eric J
 2016
 17 5 p. 567-576
10 p.
 article
39 Prostate cancer urine assay could spare biopsies Carlson, Robert H
 2016
 17 5 p. e185-
1 p.
 article
40 Proton beam therapy for medulloblastoma Jones, Bleddyn
 2016
 17 5 p. e173-
1 p.
 article
41 Proton beam therapy for medulloblastoma English, Martin
 2016
 17 5 p. e174-
1 p.
 article
42 Proton beam therapy for medulloblastoma Ramaswamy, Vijay
 2016
 17 5 p. e173-e174
nvt p.
 article
43 Proton beam therapy for medulloblastoma – Author's reply Yock, Torunn I
 2016
 17 5 p. e174-e175
nvt p.
 article
44 Quicksand Burki, Talha Khan
 2016
 17 5 p. 564-
1 p.
 article
45 Radiotherapy challenges in Uganda Burki, Talha Khan
 2016
 17 5 p. e185-
1 p.
 article
46 Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial Younes, Anas
 2016
 17 5 p. 622-631
10 p.
 article
47 Sugar tax in the UK Burki, Talha Khan
 2016
 17 5 p. e182-
1 p.
 article
48 Sulindac plus erlotinib for familial adenomatous polyposis Baker, Holly
 2016
 17 5 p. e183-
1 p.
 article
49 Targeted therapy in BRAF-mutated lung adenocarcinoma Laurie, Scott A
 2016
 17 5 p. 550-551
2 p.
 article
50 Targeting macrophages to treat pancreatic cancer Philip, Philip A
 2016
 17 5 p. 552-553
2 p.
 article
51 Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial Nywening, Timothy M
 2016
 17 5 p. 651-662
12 p.
 article
52 The EU: what's best for UK cancer research and patients? Selby, Peter
 2016
 17 5 p. 556-557
2 p.
 article
53 The metamorphosis of cancer care Swain, Kelley
 2016
 17 5 p. 563-
1 p.
 article
54 The US Cancer Moonshot initiative Aelion, C Marjorie
 2016
 17 5 p. e178-e180
nvt p.
 article
55 Time for better presentation and analysis of adverse events Mendoza, Tito
 2016
 17 5 p. 553-554
2 p.
 article
56 Tyrosine kinase inhibitors as first-line treatment in NSCLC Maemondo, Makoto
 2016
 17 5 p. 541-543
3 p.
 article
57 Under-reporting of harm in clinical trials Seruga, Bostjan
 2016
 17 5 p. e209-e219
nvt p.
 article
58 Vessel-sparing radiation and functional anatomy-based preservation for erectile function after prostate radiotherapy Lee, Jae Y
 2016
 17 5 p. e198-e208
nvt p.
 article
                             58 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands